

Effect of simvastatin on bone markers in osteopenic women: a placebo-controlled, dose-ranging trial

Submission date 26/02/2002	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 26/02/2002	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 06/09/2007	Condition category Musculoskeletal Diseases	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Judith Hsia

Contact details
George Washington University
2150 Pennsylvania Ave NW
Washington DC
United States of America
20037
+1 202 004 5461
domjah@gwumc.edu

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
N/A

Study information

Scientific Title

Study objectives

Not provided at time of registration

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Osteopenia

Interventions

1. Placebo once a day, at bedtime (qhs)
2. Simvastatin 20 mg qhs
3. Simvastatin 40 mg qhs

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Simvastatin

Primary outcome measure

Not provided at time of registration

Secondary outcome measures

Not provided at time of registration

Overall study start date

01/02/2001

Completion date

01/05/2001

Eligibility

Key inclusion criteria

1. Women with osteopenia
2. Not taking oestrogen
3. Selective oestrogen receptor modulators
4. Bisphosphonates
5. Calcitonin
6. 3-hydroxy-3-methylglutaryl coenzyme A (HMG-coA) reductase inhibitors

Participant type(s)

Patient

Age group

Not Specified

Sex

Female

Target number of participants

24

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/02/2001

Date of final enrolment

01/05/2001

Locations

Countries of recruitment

United States of America

Study participating centre

George Washington University
Washington DC
United States of America
20037

Sponsor information

Organisation

George Washington University (USA)

Sponsor details

2150 Pennsylvania Ave NW
Washington DC
United States of America
20037

Sponsor type

University/education

ROR

<https://ror.org/00y4zzh67>

Funder(s)

Funder type

Industry

Funder Name

Merck & Co. Inc. (USA) - unrestricted grant

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	Results	01/01/2002		Yes	No